Literature DB >> 10512362

Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype.

D Flamez1, P Gilon, K Moens, A Van Breusegem, D Delmeire, L A Scrocchi, J C Henquin, D J Drucker, F Schuit.   

Abstract

1-Cells from rodents and humans express different receptors recognizing hormones of the secretin-glucagon family, which--when activated--synergize with glucose in the control of insulin release. We have recently reported that isolated islets from mice homozygous for a GLP-1 receptor null mutation (GLP-1R(-/-)) exhibit a well-preserved insulin-secretory response to glucose. This observation can be interpreted in two different ways: 1) the presence of GLP-1R is not essential for the secretory response of isolated islets to glucose alone; 2) beta-cells in GLP-1R(-/-) pancreases underwent compensatory changes in response to the null mutation. To explore these possibilities, we studied islets from control GLP-IR(+/+) mice in the absence or presence of 1 pmol/l exendin (9-39)amide, a specific and potent GLP-1R antagonist. Exendin (9-39)amide (15-min exposure) reduced glucose-induced insulin secretion from both perifused and statically incubated GLP-1R(+/+) islets by 50% (P < 0.05), and reduced islet cAMP production in parallel (P < 0.001). Furthermore, GLP-1R(-/-) islets exhibited: 1) reduced cAMP accumulation in the presence of 20 mmol/l glucose (knockout islets versus control islets, 12 +/- 1 vs. 27 +/- 3 fmol x islet(-1) x 15 min(-1); P < 0.001) and exaggerated acceleration of cAMP production by 10 nmol/l glucose-dependent insulinotropic peptide (GIP) (increase over 20 mmol/l glucose by GIP in knockout islets versus control islets: 66 +/- 5 vs. 14 +/- 3 fmol x islet(-1) x 15 min(-1); P < 0.001); 2) increased mean cytosolic [Ca2+] ([Ca2+]c) at 7, 10, and 15 mmol/l glucose in knockout islets versus control islets; and 3) signs of asynchrony of [Ca2+]c oscillations between different islet subregions. In conclusion, disruption of GLP-1R signaling is associated with reduced basal but enhanced GIP-stimulated cAMP production and abnormalities in basal and glucose-stimulated [Ca2+]c. These abnormalities suggest that GLP-1R signaling is an essential upstream component of multiple beta-cell signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512362     DOI: 10.2337/diabetes.48.10.1979

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  23 in total

1.  Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation.

Authors:  Kristopher C Dozier; Elizabeth L Cureton; Rita O Kwan; Brian Curran; Javid Sadjadi; Gregory P Victorino
Journal:  Peptides       Date:  2009-06-26       Impact factor: 3.750

Review 2.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Coupling of metabolic, second messenger pathways and insulin granule dynamics in pancreatic beta-cells: a computational analysis.

Authors:  Leonid E Fridlyand; Louis H Philipson
Journal:  Prog Biophys Mol Biol       Date:  2011-09-08       Impact factor: 3.667

4.  Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells.

Authors:  I Hadjiyanni; K A Siminovitch; J S Danska; D J Drucker
Journal:  Diabetologia       Date:  2010-01-08       Impact factor: 10.122

Review 5.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

6.  Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in β-Cells to Protect From Apoptosis.

Authors:  Amelia K Linnemann; Joshua C Neuman; Therese J Battiola; Jaclyn A Wisinski; Michelle E Kimple; Dawn Belt Davis
Journal:  Mol Endocrinol       Date:  2015-05-18

7.  β Cell tone is defined by proglucagon peptides through cAMP signaling.

Authors:  Megan E Capozzi; Berit Svendsen; Sara E Encisco; Sophie L Lewandowski; Mackenzie D Martin; Haopeng Lin; Justin L Jaffe; Reilly W Coch; Jonathan M Haldeman; Patrick E MacDonald; Matthew J Merrins; David A D'Alessio; Jonathan E Campbell
Journal:  JCI Insight       Date:  2019-03-07

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.

Authors:  Diva D De León; Changhong Li; Madeleine I Delson; Franz M Matschinsky; Charles A Stanley; Doris A Stoffers
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

10.  Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.

Authors:  Yanan Hou; Stephen A Ernst; Kaeli Heidenreich; John A Williams
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-05       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.